Innate Pharma (IPH) — Tangible Net Worth Ratio
Innate Pharma (IPH) has a Tangible Net Worth Ratio of 100.0% as of June 2025. This metric is calculated by deducting intangible assets (€0.00) from net assets (€5.14 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See Innate Pharma current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Innate Pharma Tangible Net Worth Ratio (2003–2024)
This chart shows how Innate Pharma's Tangible Net Worth Ratio has changed across 22 annual periods from 2003 to 2024. As of June 2025, the ratio stands at 100.0%, reflecting net assets of €5.14 Million with intangible assets of €0.00 EUR. See Innate Pharma defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Innate Pharma (2003–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Innate Pharma from 2003 to 2024, covering 22 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Innate Pharma (IPH) total market value.
| Year | Tangible NW Ratio | Net Assets (EUR) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 100.0% | €8.83 Million | €0.00 | €111.06 Million | ▲ +0.8 pp |
| 2023 | 99.2% | €51.90 Million | €416.00K | €184.19 Million | ▲ +77.8 pp |
| 2022 | 21.4% | €54.15 Million | €42.55 Million | €207.86 Million | ▼ -37.5 pp |
| 2021 | 58.9% | €107.44 Million | €44.19 Million | €267.50 Million | ▼ -11.5 pp |
| 2020 | 70.3% | €155.97 Million | €46.29 Million | €307.42 Million | ▲ +14.9 pp |
| 2019 | 55.4% | €217.42 Million | €96.97 Million | €401.36 Million | ▲ +5.9 pp |
| 2018 | 49.5% | €167.24 Million | €84.53 Million | €451.22 Million | ▲ +3.2 pp |
| 2017 | 46.3% | €85.96 Million | €46.19 Million | €255.02 Million | ▼ -43.2 pp |
| 2016 | 89.5% | €86.17 Million | €9.07 Million | €281.58 Million | ▲ +3.0 pp |
| 2015 | 86.5% | €72.07 Million | €9.73 Million | €305.96 Million | ▼ -6.3 pp |
| 2014 | 92.8% | €74.63 Million | €5.36 Million | €90.69 Million | ▼ -7.2 pp |
| 2013 | 100.0% | €40.29 Million | €0.00 | €55.88 Million | ▲ +0.0 pp |
| 2012 | 100.0% | €23.36 Million | €0.00 | €48.30 Million | ▲ +0.0 pp |
| 2011 | 100.0% | €26.62 Million | €0.00 | €60.11 Million | ▲ +0.0 pp |
| 2010 | 100.0% | €33.52 Million | €0.00 | €48.01 Million | ▲ +0.0 pp |
| 2009 | 100.0% | €47.12 Million | €0.00 | €64.22 Million | ▲ +0.0 pp |
| 2008 | 100.0% | €41.34 Million | €0.00 | €60.86 Million | ▲ +0.0 pp |
| 2007 | 100.0% | €49.61 Million | €0.00 | €63.15 Million | ▲ +0.0 pp |
| 2006 | 100.0% | €56.37 Million | €0.00 | €69.25 Million | ▲ +0.2 pp |
| 2005 | 99.8% | €20.07 Million | €34.00K | €24.77 Million | ▲ +1.4 pp |
| 2004 | 98.4% | €25.01 Million | €392.00K | €29.51 Million | ▲ +0.8 pp |
| 2003 | 97.6% | €15.11 Million | €361.00K | €20.38 Million | — |